Hi jadite , Pete ,
This is what I got out of Mr Simes reply
They will not release the results of a major catalyst prior to the merger with ANI because the news back in sept 2012 of a successful 9th and final review did not impact the stock , lack of market reaction !
Well , what does that have to do with including the value into the merger deal ? And releasing final safety results !!!
Final safety results is being held back as if it has NO Value ,
Efficacy is a short study , and the cost is relatively low compared to Safety study ,
Anything short of reporting safety results PRIOR to merger is obsurd ! And needs to be looked at closely by all investors ! There was zero PR to explain the importance of a proven safety study of this kind, it is the first FDA proven safety for this indication... Moreso , there is material information included in safety results that will support CV Benifits , again not included in this merger, Simes made it clear that bpax would meet with FDA to explore how the two new trials would be designed , did Bpax ask to use P & G efficacy results ? Or 505a ?
There are over 4 mil scripts in USA for women with low T using modified doses of FDA approved male T
We have two FDA approved drugs with little to no income , one a male T drug that news has been withheld from shareholders for almost. Year now. A cancer vaccine portfolio valued at 1-2 million dollars , yet evaluated for 9 mil when CEGE was acquired into Bpax , 4 orphan drug designations, 17 ongoing trials
How do they expect shareholders to look at this ???
This is wrong ! and people should write their own letter and let our BOD know of our concerns ! Do something about it, the merger may be the right move for shareholders, but first provide answers as to where shareholders value are taken into account ! And explain why our portfolio is being undervalued ,
Jmho
GLTA
Market Data 
Markets 
AI
